The meeting brought together over 200 specialists from 25 countries, representing a truly international effort to advance research and clinical practice in the field of kidney diseases associated with monoclonal gammopathies.
The scientific programme featured a rich series of sessions addressing key areas in the field, including new pathophysiological insights into monoclonal gammopathies and kidney disease, innovations in diagnostic tools and biomarkers, emerging therapeutic strategies, and the latest updates from ongoing clinical trials.